Notice of Results
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notice of Results and Investor Presentation
LONDON, 12 September 2022: Celadon Pharmaceuticals Plc (AIM: CEL), a leading UK based pharmaceutical company focused on the development and supply of natural cannabis-based medicines, will announce its maiden results for the six months ended 30 June 2022 on Thursday 29 September 2022.
Analyst Briefing: 9.00am, Thursday 29 September 2022
Management will host a virtual analyst presentation followed by a Q&A session at 9.00am BST on Thursday 29 September 2022. Analysts wishing to join should register their interest by contacting celadon@powerscourt-group.com .
Investor Presentation: 2.30pm, Thursday 29 September 2022
Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 2.30pm BST on Thursday 29 September 2022.
The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am on Thursday 29 September 2022 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
Investors who already follow Celadon on the Investor Meet Company platform will automatically receive an invitation to the event.
Enquiries:
|
Celadon Pharmaceuticals Plc |
|
|
James Short Arthur Wakeley |
Via Powerscourt |
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Andrew Potts / Patrick Dolaghan / Bobbie Hilliam |
+44 (0)20 7523 8000 |
|
|
|
|
Powerscourt Group |
|
|
Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil |
+44 (0)20 7250 1446 celadon@powerscourt-group.com |
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of natural cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office License to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.
For further information please visit our website www.celadonpharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 32 minutes ago Origin Enterprises (CDI)
- 34 minutes ago Origin Enterprises (CDI)
- 1 hour ago SSP Group
- 2 hours ago Latham (James)
- 2 hours ago LSL Property Services